Company: REVB
Filing Date: 2025-09-30
Form Type: S-3/A
Source: 0001193125-25-223617
Chunk: 6

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-09-30
Form: S-3/A
Chunk 6
---
, which are incorporated herein by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including the applicable prospectus supplement. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned elsewhere in this prospectus.

<div align='center'>4</div>

We are not selling any securities in this prospectus. All proceeds from the resale of the shares of common stock offered by this prospectus will belong to the Selling Stockholders. We will not receive any proceeds from the resale of the shares of common stock by the Selling Stockholders. We may receive proceeds from the cash exercise of the Class I Common Stock Warrants, which, if exercised in cash at the current exercise price with respect to all 13,065,000 shares of common stock, which are exercisable in cash, would result in gross proceeds of approximately $28,743,000 to us. Any cash proceeds from the exercise of Class I Common Stock Warrants will be used to advance our preclinical and clinical development plans, and to fund working capital and general corporate purposes using any remaining amounts.

<div align='center'>5

PRIVATE PLACEMENT OF WARRANTS</div>

On September 10, 2024, the Company entered into Inducement Letters with three holders (the “Holders”) of 13,065,000 Class H Common Stock Warrants, issued on May 29, 2025 exercisable for 4,355,000 shares of common stock with an exercise price of $2.20 per share of common stock. Pursuant to the Inducement Letters, the Holders agreed to the immediate cash exercise of their 13,065,000 Class H Common Stock Warrants to purchase an aggregate of 4,355,000 shares of the Company’s common stock at an exercise price of $2.20 per share, and the Company’s agreement to issue 13,065,000 Class I Common Stock Warrants exercisable for a total of up to 13,065,000 shares of common stock, as described below. The Company received aggregate gross proceeds of $9,581,